We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
- Authors
Chang-Hyun Kim; Sun-Je Woo; Park, Jung-Sun; Hye-Sung Kim; Park, Mi-Young; Park, Sung-Dong; Yong-Kil Hong; Tai-Gyu Kim
- Abstract
Although chemotherapy remains among the best treatment options for most cancers, adjuvant therapies such as dendritic cell (DC)-based immunotherapy have been added to treatment protocols to destroy residual tumour cells. Combination treatment with low-dose temozolomide (TMZ) chemotherapy followed by vaccination with TAT-survivin-pulsed DCs enhanced T-cell responses specific for survivin and improved survival rate, as compared with DC alone or TMZ alone. Moreover, antigen-specific immunity appears to be mediated by CD8+ T cells, as determined by in vitro T-cell subset depletion. These studies demonstrated that a combination of low-dose TMZ chemotherapy and TAT-based DC immunotherapy may be a novel strategy for safe and effective treatment of malignant gliomas.
- Publication
Immunology, 2007, Vol 122, Issue 4, p615
- ISSN
0019-2805
- Publication type
Academic Journal
- DOI
10.1111/j.1365-2567.2007.02680.x